Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3358 results

Sort By:

A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.

Study ID: NCT05454566
Start Date: 2025-11-15
End Date: 2027-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

18

Intervention / Treatment

ICM-203

Sponsor

ICM Co. Ltd.

Source: clinicaltrials.gov

Share:
Add to list

Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer

Study ID: NCT06654466
Start Date: 2025-09-01
End Date: 2027-09
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Nest, an electronic medical record (EMR)-integrated software platform to deliver longitudinal, genetics-based care at scale.

Sponsor

Nest Genomics

Source: clinicaltrials.gov

Share:
Add to list

The Oh Happy Day Class - Digital Connections (OHDC-DC): A Pilot Study

Study ID: NCT06206226
Start Date: 2025-07
End Date: 2026-05
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

8

Intervention / Treatment

OHDC-DC

Sponsor

University of Wisconsin, Madison

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of Moringa Oleifera Leaf Extract Versus Sodium Hypochlorite in Pulpectomy of Nonvital Primary Molars

Study ID: NCT06948526
Start Date: 2025-06-01
End Date: 2026-08-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Moringa Oleifera Leaf Extract

Sodium Hypochlorite 1%

Sponsor

Cairo University

Source: clinicaltrials.gov

Share:
Add to list

Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®

Study ID: NCT06504966
Start Date: 2025-10
End Date: 2027-10
Study Type

Interventional

Study Phase

Phase3

No. of Participants

440

Intervention / Treatment

MAB-22

Prolia®

Sponsor

Xentria, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Efficacy of Adjunctive At-Home Photodynamic Therapy (aPDT) in the Treatment of Peri-Implant Mucositis

Study ID: NCT06859866
Start Date: 2025-06
End Date: 2027-02
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

Standard oral hygiene

The addition of home-based dual-light photodynamic therapy (Lumorinse® + Lumoral®)

Sponsor

Healthy

Source: clinicaltrials.gov

Share:
Add to list

A Study of Iguratimod in Combination With Tofacitinib in RA Patients

Study ID: NCT06945666
Start Date: 2025-08-01
End Date: 2027-05-31
Study Type

Interventional

Study Phase

Phase4

No. of Participants

200

Intervention / Treatment

Combined therapy of Iguratimod and tofacitinib

Sponsor

J IE Chang

Source: clinicaltrials.gov

Share:
Add to list

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

Study ID: NCT06525766
Start Date: 2025-10-15
End Date: 2030-10-15
Study Type

Interventional

Study Phase

Phase2

No. of Participants

35

Intervention / Treatment

Biospecimen Collection

Bone Scan

Capecitabine

Computed Tomography

Magnetic Resonance Imaging

Administration questionnaire

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

Helpline Pilot Factorial Trial

Study ID: NCT06591026
Start Date: 2025-12-01
End Date: 2027-07-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

120

Intervention / Treatment

Standard Helpline (SH)

Motivational Interviewing (MI)

Coping Skills Training (CST)

Automated Text Messaging (ATM)

Sponsor

The National Center on Addiction and Substance Abuse at Columbia University

Source: clinicaltrials.gov

Share:
Add to list

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Study ID: NCT06202066
Start Date: 2025-06-15
End Date: 2028-10-15
Study Type

Interventional

Study Phase

Phase2

No. of Participants

132

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Incomplete Freund''s Adjuvant

Magnetic Resonance Imaging

Sargramostim

SVN53-67/M57-KLH Peptide Vaccine

Temozolomide

Sponsor

Roswell Park Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list